Mudrick Capital Acquisition Corporation (NASDAQ:MUDS)
Mudrick Capital Acquisition Corporation (NASDAQ:MUDS) represented a move of 0 percent or $-0.03 per share and closed its previous day trading session at $9.9. 0 Shares were traded in the last trading session with an Average Volume of 32.2 Million Shares. The stock currently has a Market Capitalization of 205.92 Million.
Mudrick Capital Acquisition Corporation is a blank check company. It formed for the purpose of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Mudrick Capital Acquisition Corporation is based in New York.
Right now, the stock has a 50-Day Simple Moving Average of $1.36 and 200-Day Simple Moving Average of $2.18. Its Price to Free Cash Flow is 0 and Price to Book of 51.56.
Analyst’s recommended the stock as 0 where 1 represents Strong Buy and 5 represents Sell.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
In the last trading session, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) added its value by 0% closing at the price of $7.8. The stock currently has market capitalization of 186.65 Million, with average volume of 204.65 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is showing beta of 1.17. This particular value of beta suggests that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has historically moved 117% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Xenon Pharmaceuticals Inc. (NASDAQ:XENE) is at $-1.64.
The stock currently has RSI of 32.68. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) topped its 52-week high price of $15.92 on 09/07/18 and 52-Week Low Price of $ 2.35 on 12/08/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 7.73% and monthly volatility of 6.87% respectively.